Success Metrics

Clinical Success Rate
92.1%

Based on 35 completed trials

Completion Rate
92%(35/38)
Active Trials
17(26%)
Results Posted
60%(21 trials)
Terminated
3(5%)

Phase Distribution

Ph phase_1
15
23%
Ph phase_4
13
20%
Ph not_applicable
11
17%
Ph early_phase_1
1
2%
Ph phase_2
15
23%
Ph phase_3
10
15%

Phase Distribution

16

Early Stage

15

Mid Stage

23

Late Stage

Phase Distribution65 total trials
Early Phase 1First-in-human
1(1.5%)
Phase 1Safety & dosage
15(23.1%)
Phase 2Efficacy & side effects
15(23.1%)
Phase 3Large-scale testing
10(15.4%)
Phase 4Post-market surveillance
13(20.0%)
N/ANon-phased studies
11(16.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

35 of 40 finished

Non-Completion Rate

12.5%

5 ended early

Currently Active

17

trials recruiting

Total Trials

65

all time

Status Distribution
Active(25)
Completed(35)
Terminated(5)

Detailed Status

Completed35
Recruiting15
Not yet recruiting8
Terminated3
Withdrawn2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
65
Active
17
Success Rate
92.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.5%)
Phase 115 (23.1%)
Phase 215 (23.1%)
Phase 310 (15.4%)
Phase 413 (20.0%)
N/A11 (16.9%)

Trials by Status

completed3554%
terminated35%
recruiting1523%
not_yet_recruiting812%
withdrawn23%
active_not_recruiting23%

Recent Activity

Clinical Trials (65)

Showing 20 of 65 trialsScroll for more
NCT06652737Phase 1

Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

Completed
NCT06862453Phase 1

Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults

Recruiting
NCT06546709Phase 1

DMID 23-0015; Lassa Fever CVD 1000

Active Not Recruiting
NCT06909565Phase 4

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Recruiting
NCT07035301Not Applicable

Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures

Completed
NCT07441226Phase 2

Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients

Recruiting
NCT07436286Not Applicable

Intra-Umbilical Vein Oxytocin Injection as an Adjunct to Active Management of the Third Stage of Labour

Completed
NCT07415252Phase 3

SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years

Not Yet Recruiting
NCT07394036Phase 2

Effect of Ipratropium Bromide on EILO

Not Yet Recruiting
NCT07362992Early Phase 1

Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery

Not Yet Recruiting
NCT06217939Not Applicable

Early Intravenous Hydrocortisone in Sepsis

Recruiting
NCT06680128Phase 1

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

Recruiting
NCT07276633Not Applicable

Use of Subanesthetic Dose Propofol Before Extubation

Completed
NCT04166877Phase 4

Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

Recruiting
NCT07217873Phase 2

IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study

Recruiting
NCT06828666Phase 1

A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee

Recruiting
NCT06237049Phase 2

A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

Completed
NCT06767358Phase 3

Ketamine Sedation in the ICU (KANINE) RCT

Not Yet Recruiting
NCT07098780Phase 4

Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery

Recruiting
NCT07039318Phase 2

Mesenchymal Stem Cell Therapy in Diabetic Kidney Disease-A Double-blind, Placebo-controlled, Randomized Clinical Trial

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
65